PATH vs PRAX · P/E 19, rev $1.61B vs rev $8.6M
Uipath Inc (PATH) versus Praxis Precision Medicines Inc (PRAX) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Praxis Precision Medicines Inc (PRAX) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported PRAX revenue for 2024-12-31 was $8.6M. Net income was -$58.7M. Revenue was up 249.5% from 2023-12-31 to 2024-12-31. PRAX currently screens at market cap $7.38B.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. PRAX currently screens at market cap $7.38B.
Not investment advice. Open the PATH and PRAX stock pages for the full models.
Not investment advice.